Medifast Targets Q4 Profit as Its Coach Network Shrinks
Medifast forecasts breakeven to profitable fourth-quarter earnings after restructuring charges and a shrinking coach network deepened its quarterly loss.

Medifast reported a third-quarter net loss of $17.51 million and forecast fourth-quarter earnings of $0.00 to $0.25 per share despite continued declines in its active earning coaches.
Medifast, Inc. (NYSE: MED) expects to reach breakeven or profitability in the fourth quarter after reporting a sharply wider third-quarter loss, even as the metabolic health and wellness company anticipates further contraction in its coach network.
The company forecast fourth-quarter earnings of $0.00 to $0.25 per share on revenue of $55 million to $75 million. That outlook contrasts with a third-quarter net loss of $17.51 million, or $1.57 per share, and a projected loss for fiscal 2026.
Shares rose 5.51% to $12.52 in early trading on October 26, according to Nasdaq Markets. The gain stood at 2.95% as of 15:15:41 GMT, leaving the stock higher but off its earlier percentage advance.
Coach departures outweigh productivity gains
The central operating challenge is the shrinking number of active earning coaches. Medifast reported 10,200 in the third quarter, down 47.7% from 19,500 a year earlier, and expects that number to keep falling through the end of 2026.
Revenue declined 19.4% to $72.05 million from $89.41 million, primarily because of the smaller coach network. Chief Executive Officer Nick Johnson said sales met company guidance and coach productivity improved year over year for the fourth consecutive quarter.
Those results point in different directions: the remaining coaches are becoming more productive, but that improvement has not been enough to prevent an overall revenue decline. With further coach attrition expected, the fourth-quarter earnings outlook does not signal that the company's sales pressure has ended.
Restructuring widens the reported loss
Chief Executive Officer Nick Johnson said sales met company guidance and coach productivity improved year over year for the fourth consecutive quarter.
The third-quarter net loss compared with a loss of $2.26 million, or $0.21 per share, a year earlier. On an adjusted basis, Medifast reported a net loss of $2.1 million, or $0.19 per share, substantially smaller than its reported loss but still below breakeven.
Selling, general and administrative expenses increased 4.8%, primarily because of a $13.8 million increase in Catalyst Restructuring charges. The operating loss widened to $19.4 million from $4.1 million.
Gross profit fell 19.5% to $50.04 million from $62.16 million. Lower sales volumes and Catalyst Restructuring charges weighed on the result, while costs incurred a year earlier to reformulate the Essential product line partially softened the comparison.
Quarterly recovery would not erase the annual loss
For fiscal 2026, Medifast expects a loss of $1.80 to $2.05 per share and an adjusted loss of $0.45 to $0.70 per share, with revenue between $280 million and $300 million.
The fourth-quarter revenue range spans outcomes both below and above the third quarter's $72.05 million. Profitability therefore need not depend on sequential sales growth across the entire forecast range. The immediate test is whether Medifast can deliver its projected earnings while absorbing continued coach departures; even a profitable finish would leave the company forecasting a loss for the full year.
Sources
- Medifast Q3 Loss Widens, Sees Profit In Q4, Loss In FY26; Shares Up — Nasdaq Markets
Photo: Eren098566 · Pixabay Content License — source


